15th AnnuAl EvEnt

AnnuAl EvEnt

February 11-12, 2013 The Waldorf Astoria New York

-2-

Now in its fifteenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on leading publicly-traded biotech companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.

Top 10 Reasons to attend

Present your company story to an audience of targeted investors.

Hear the Washington perspective on the Affordable Care Act, debt ceiling, and other timely policy developments affecting the industry.

Evaluate fresh investment opportunities including compatible, complementary and competitive companies.

Learn about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables.

Attend fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2013.

Gain access to BIO’s 1x1 Partnering System for scouting potential deal partners and optimizing your time at the event.

Access presentations from more than 140 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences.

Get the pulse on the current and proposed investment trends in biotechnology.

Network with peers, investors and potential partners attending the conference.

It’s the first NYC biotech conference of the year, kicking off a week of key industry events that you don’t want to miss.

12

3

4

5

6

7

8

9

10

-3-

Tom Brakel, MDPortfolio Manager, Federated Kaufmann Funds

Advisory Committee

John ChambersManaging Director & Head of Healthcare Investment Banking, Roth Capital Partners

Michael Gilman, PhD Senior Vice President Early-Stage Programs, Biogen Idec

Peter Kolchinksky, PhDManaging Partner, RA Capital Management, LLC

Oleg NodelmanFounder & Managing Director, EcoR1 Capital

Joel SendekManaging Director, Head Healthcare Equity Research, Stifel Nicolaus

Michael HayVice President, BioMedTracker Product Manager, Sagient Research Systems

Arlene MorrisCEO, Syndax Pharmaceuticals

David Sable, MDPortfolio Manager, Special Situations Fund

Nathan Tinker, PhDExecutive Director New York Biotechnology Association

-4-

Fireside chats feature candid discussions between biopharma executives and Wall Street analysts. Hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2013.

Fireside Chats

Jean-Jacques BienaiméChief Executive Officer BioMarin Pharmaceutical Inc.

N. Anthony ColesChairman & CEO Onyx Pharmaceuticals, Inc.

Robert HuginChairman and Chief Executive Officer Celgene Corporation

John C. Lechleiter, PhDChairman, President and CEO Eli Lilly and Company

John F. Milligan, PhDPresident and Chief Operating Officer, Gilead Sciences, Inc.

-5-

Word on the Street: The Buy-Side View for 2013Monday, February 11th, 12:00pm – 12:55pmPortfolio managers and senior buy-side analysts forecast the year ahead in biotech. This lively panel discussion will be primed with the results of this year’s Investor Perception Study, conducted by BIO’s Industry Analysis Team and ISI Group. Panelists will field a range of questions from valuations and volatility to challenges and opportunities facing institutional investors today.

Moderator:• Mark Schoenebaum, MD, Senior Managing Director and Head, Healthcare Research, ISI Group

Panelists:• Samuel D. Isaly, Managing Partner, OrbiMed Advisors• Oleg Nodelman, Founder & Managing Director, EcoR1 Capital • Nathan Sadeghi-Nejad, Partner, Palkon Capital Management

Tales From the Wild West (Wing): Reflections from White House Chiefs of StaffTuesday, February 12th, 4:00pm – 4:55pmThe election chips have fallen and the country is gearing up for another four years of economic challenges and political wrangling. With divided government, compromises will be difficult and time consuming to reach, but will be necessary to deal with big issues the U.S. faces. Although the fiscal cliff has been averted for now, an unsteady economy and concerns over U.S. debt remain. This session will feature two former White House Chiefs of Staff who have served in the trenches under President Bill Clinton and President George W. Bush. BIO’s CEO and former Congressman, James C. Greenwood, will lead an in depth and lively discussion between Joshua Bolten and John Podesta, who will proffer their views of the political landscape, the outlook for the next four years, the outcome of these key issues and more.

Moderator:• James C. Greenwood, President & CEO, BIO

Panelists:• Joshua Bolten, 22nd White House Chief of Staff and Managing Director, Rock Creek Global Advisors• John Podesta, Former White House Chief of Staff and Founder and Chair,

Center for American Progress

Plenary Sessions

James C. Greenwood Joshua Bolten John PodestaMark Schoenebaum Samuel D. Isaly Oleg Nodelman Nathan Sadeghi-Nejad

-6-

Oncology: Panning for Gold—Prospecting the Pancreatic PipelineMonday, February 11th, 10:30am - 11:25amThough pancreatic cancer is the 4th leading cancer malignancy, resulting in nearly 37,000 deaths a year in the US, the pipeline has garnered less attention from industry and the investment community than other oncology indications. There are only two currently approved single agent therapies for this serious disease, but combination treatment regimens are showing tremendous promise yielding a significant increase in overall survival rates. With several phase II and III trials now in the works and positive readouts expected in 2013, the industry is becoming much more intrigued by this potentially underserved space. Hear clinical experts entrenched in the pancreatic cancer late stage treatment pipeline proffer their insights on the future of the disease.

Moderator:• Brian Klein, MD, Vice President & Senior Biotechnology Analyst, Stifel, Nicolaus & Company

Panelists:• John Chabot, MD, FACS, Chief, Division of GI/Endocrine Surgery and Executive Director,

Pancreas Center, New York Presbyterian Hospital/Columbia University • Stewart M. Kroll, Senior Vice President, Clinical Operations and Biostatistics,

Threshold Pharmaceuticals • Peter Laivins, Vice President, Late Stage Drug Development, Merrimack Pharmaceuticals • Kenneth H. Yu, MD, Assistant Professor, Memorial Sloan-Kettering Cancer Center

Therapeutic Workshops

-7-

Orphan Drugs: Making Rare Diseases RarerTuesday, February 12th, 9:00am - 9:55amThe signing of FDASIA by President Obama in July reinforces the country’s commitment to fostering innovation for rare diseases. With a record 460 medicines in late-stage clinical trials, biopharmaceutical companies have embraced rare disease medicine and are rapidly developing the pipeline with hopes of achieving the ever elusive blockbuster drug. Some companies have even taken a step beyond and focused primarily on ultra rare disease, potentially providing an even more compelling opportunity. This panel will provide an in-depth analysis of the thriving market opportunity that is rare disease by featuring industry, clinical and regulatory experts specializing in this exciting field.

Moderator:• Ritu S. Baral, Principal, Sr. Analyst- Biotechnology Equity Research, Genuity Partners

Panelists:• Marc Beer, Chief Executive Officer, Aegerion Pharmaceuticals• John F. Crowley, Chairman & CEO, Amicus Therapeutics • Pamela Gavin, Senior Vice President, National Organization for Rare Disorders (NORD)• Hans GCP Schikan, PharmD, Chief Executive Officer, Prosensa • Alvin V. Shih, MD, Chief Operating Officer, Pfizer Rare Disease Research Unit

Oncology: The CLL Chronicles—The Next Chapter in Clinical DevelopmentsTuesday, February 12th, 12:00pm - 12:55pmModerator:

• Joel Sendek, Managing Director & Biotechnology Analyst, Stifel Nicolaus & Company

Panelists:• Jacqueline Barrientos, MD, Assistant Professor of Medicine, Hofstra North Shore-LIJ School of

Medicine CLL Research and Treatment Program • John F. Gerecitano, MD, PhD, Medical Oncologist & Hematologist, Memorial Sloan-Kettering Cancer Center• Kanti Rai, MD, Joel Finkelstein Cancer Foundation Professor of Medicine and Professor of

Molecular Medicine, Hofstra North Shore-LIJ School of Medicine

-8-

Show Me the Money: Reimbursement in an ACA World Monday, February 11, 9:00am - 9:55amWith many key provisions of the Affordable Care Act (ACA) slated to take effect in 2013 and beyond, the industry is facing sweeping changes to the managed care and reimbursement road map. Additionally, nearly 30 million more Americans will now have access to health insurance. How will this new environment affect relationships between patients, payors, providers and biopharma companies? How could changes to federal health plans and the creation of state-run insurance exchanges alter biopharma company strategy, from business development to R&D activities? This reimbursement roundtable will feature payors, providers, and other stakeholders from across the industry discussing ACA implementation and the wider reimbursement landscape.

Moderator:• Roger Longman, Chief Executive Officer, Real Endpoints

Panelists:• Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan-Kettering Cancer Center • Rena Conti, PhD, Assistant Professor of Health Policy & Economics, University of Chicago • Ed Pezalla, MD, MPH, National Medical Director for Pharmacy Policy and Strategy, Office of the Chief Medical Officer, Aetna • Cynthia Smith, Vice President, Market Access & Commercial Development, Affymax

The Road Less Traveled: Alternative Avenues to Public MarketsTuesday, February 12th, 1:30pm - 2:25pmWhile an IPO has long been a preferred way to go public, an increasing number of companies have employed alternate routes to the public markets, using reverse mergers, Form-10 self-filings, and variations of each to avoid the expense, uncertainty, and complexity of the IPO process. In particular, these alternate avenues may offer advantages by sepa-rating the straightforward process of becoming a publicly-filing company from less predictable fund raising. Hear an experienced attorney, executives, and crossover investors who have traveledthese new paths discuss lessons learned, deal structures, and how recent legislation like the JOBS Act could affect public exits.

Moderator• William Hicks, Member, Mintz Levin

Panelists:• Charles Crain, Manager, Policy & Research, BIO • Michelle Dipp, MD, PhD, Chief Executive Officer & Co-Founder, OvaScience • Daniel B. Dubin, MD, Vice Chairman & Founder, MEDACorp, Leerink Swann• Peter Kolchinsky, PhD, Managing Partner, RA Capital

Putting a Ring on It—When Drug Development Partnerships Become AcquisitionsTuesday, February 12th, 12:00pm-12:55pmMany recent biopharma acquisitions have started as drug development collaborations including GlaxoSmithKline’s takeover of Human Genome Sciences and Amgen’s purchase of Micromet. How do traditional drug development relationships grow into all-out acquisitions? What business or clinical considerations can prompt the larger company to “take the plunge” and acquire their smaller partner? What deal-breakers should both parties watch for? The panel will feature seasoned business development executives discussing the do’s and don’t’s of taking biopharma collaborations to the next level.

Business Roundtables

-9-

Moderator:• Jeff Stewart, Senior Engagement Manager, Campbell Alliance

Panelists:• Michael Gilman, PhD, Senior Vice President, Early Stage Programs, Biogen Idec• Demetrios Kydonieus, Esq., Vice President, Strategy, Alliances & Transactions, Bristol Myers-Squibb Company• Michael Margolis, RPh, Managing Director, ROTH Capital Partners• Effie Toshav, Partner, Corporate, Fenwick & West LLP

Small Companies Thinking Big—China Tactical StrategiesMonday, February 11th, 3:30pm - 4:25pmBig pharmaceutical companies aren’t the only ones investing in China. Emerging and mid-sized biotech companies are also exploring ways to enter China’s lucrative market and maximize their investment in the country. With more limited resources than multinational biopharma companies, how can these smaller companies operate efficiently and give Chinese patients access to their innovative products? What deal making strategies have proven successful? Industry experts and biotech executives will tackle the tough questions surrounding operational tactics in China.

Moderator:• Jimmy Zhang, PhD, MBA, Managing Director, MSD Early Investments – Greater China, Merck & Co., Inc.

Panelists:• Friedhelm Blobel, PhD, President, CEO, & Director, SciClone Pharmaceuticals• Alan Eisenberg, Executive Vice President, Business Development and Emerging Companies Section, BIO• Kewen Jin, Managing Director, Nimbus Innoworks• Laurence Reid, PhD, Senior Vice President, Chief Business Officer, Alnylam Pharmaceuticals

How the Other Half Lives: What’s Happening in Venture and Why it MattersMonday, February 11th, 2:00pm - 2:55pmThe primordial soup of private biotech was supposed to give rise to a stronger, broader public market and provide mature companies with new sources of competitive advantage in the form of in-licensed drug candidates. However, the VC world is shrinking and in 2012 we hit the lowest number of first time financings for biotechs in 15 years. The number of firms investing in biotech has also decreased substantially and new patents at tech transfer offices are collecting dust. While pharma venture and philanthropic venture firms are stepping into the void, other private funding sourc-es have moved to public markets with PIPEs and VIPEs. Will the drop in private funding be a future headache for the public investor that has long depended on new technologies percolating up to public exchanges? As players and strategies are shifting at the private/public intersection, and new financing models are being tested, what should the public investor be aware of? Are there new compelling investing opportunities in 2013 on the private side?

Moderator:• Jeffrey A. Baumel, Partner, SNR Denton

Panelists:• Arlene M. Morris, Chief Executive Officer, Syndax Pharmaceuticals• Stelios Papadopoulos, PhD, Chairman, Exelixis, Inc.• Dennis Purcell, Senior Managing Partner, Aisling Capital• David Sable, MD, Portfolio Manager, Special Situations Fund

-10-

The 2013 BIO CEO & Investor Conference will better accommodate the growing diversity of investors and companies. While the majority of presenting companies at this event are publicly traded, with about half trading with market capitalizations above $100M, for the first time this meeting will also include a unique track that features up to 25 high-caliber and established private company presentations.

PuBLIC COMPANIESAastrom BiosciencesACADIA PharmaceuticalsAddex TherapeuticsAdociaAdvanced Cell Technology ADVENTRX PharmaceuticalsAegerionAffymax AgenusAlkermes plcAlnylam PharmaceuticalsAnteo DiagnosticsAnthera PharmaceuticalsAntisense TherapeuticsApricus BiosciencesAradigm Corp.Arena PharmaceuticalsAstex PharmaceuticalsAthersysAtossa Genetics BiodelBioDelivery Sciences InternationalBioLineRx Ltd.Biotie TherapiesCatalyst Pharmaceutical PartnersCEL-SCI CorporationCempra ChemoCentryx Cleveland BioLabsCyclacel PharmaceuticalsCytokineticsCytomedixCytRx CorporationDARA BioSciencesDiaMedicaDURECT CorporationEpiCept CorporationEternity Healthcare

ExelixisFuriex PharmaceuticalsGalena BioPharmaGENFITGeoVax LabsGTxHorizon PharmaiCo TherapeuticsIdenix PharmaceuticalsIdera PharmaceuticalsImmunoCellular TherapeuticsImmunoGenImmunovaccineInnovus PharmaInovio PharmaceuticalsIntercept PharmaceuticalsKeryx Biopharmaceuticals Lexicon PharmaceuticalsMDxHealthNanoViricidesNavidea NeoStemNeuralstemNewron Pharmaceuticals S.p.A.NicOx S.A.NovaBay PharmaceuticalsNovavaxNovelos TherapeuticsNPS PharmaceuticalsNymox Pharmaceutical CorporationOculus Innovative Sciences Ohr PharmaceuticalOncoGenex PharmaceuticalsOncolytics BiotechOncoSec Medical Opexa TherapeuticsOragenicsOrexigenOvaScience

OXiGENEOxygen BiotherapeuticsPalatin Technologies PozenPrima Biomed ProMetic Life Sciences Protalix BioTherapeutics Provectus PharmaceuticalspSiVida Corp.Q Therapeutics Raptor PharmaceuticalRegulus TherapeuticsReNeuronRepros TherapeuticsResverlogix Corp.RetrophinRigel PharmaceuticalsRXi PharmaceuticalsSciClone Pharmaceuticals SoligenixStallergenesStemCellsSucampo PharmaceuticalsSynergy PharmaceuticalsSynthetic BiologicsTargacept Tekmira Pharmaceuticals Corp.TengionTG TherapeuticsTiGenix N.V.Tonix PharmaceuticalsTranscept PharmaceuticalsTransition TherapeuticsTranzymeVenaxis VerastemVirtualScopicsZalicus Zealand Pharma A/SZIOPHARM Oncology

PRIVATE COMPANIESActinium PharmaceuticalsALS Therapy Development Institute** Aratana TherapeuticsCatabasis PharmaceuticalsCoLucid PharmaceuticalsFate TherapeuticsFive Prime TherapeuticsFORMA TherapeuticsGlobeImmuneGood Start GeneticsHydra BiosciencesImmune Design Corp.KaloBios PharmaceuticalsKineMedKinex PharmaceuticalsLeukemia & Lymphoma Society**Melanoma Research Alliance**Mersana TherapeuticsThe Michael J. Fox Foundation**Mirna TherapeuticsOnconova TherapeuticsPolynomaPromediorProsensa TherapeuticsProteon TherapeuticsRadius HealthRegado BiosciencesSutro BiopharmaSyndax PharmaceuticalsTobira TherapeuticsTrevenaTVAX BiomedicaluniQureZafgen

* As of 01/31/2013 ** Patient Advocacy Group

Presenting Companies*

Sign up now to present. Email Sondra Behan at sbehan@bio.org or call (866) 356-5155 for more information.

Presenting Companies

-11-

11:11 CapitalACAP International, Inc.Acers BioMedicalActin BiomedAegis Capital Corp.Aisling CapitalAkana CapitalAlpine FundsAmerican CapitalAmerican PortfoliosApis CapitalApjohn VenturesApposite CapitalArthritis FoundationAscendiant Capital Markets LLCAspire CapitalATEL VenturesAthyrium Capital ManagementAtika Capital Management, LLCAtlantic Capital GroupAtlantis InvestmentAtlas VentureAuriga Capital ManagementAvior CapitalAxon Healthcare PartnersBain CapitalBank of America Merrill LynchBarclaysBawcapBaxter Healthcare CorporationBBABC CapitalBDC Venture CapitalBearing Circle Capital, LPBifrost Capital, LLCBioRevolution Capital, LLCBioYieldsBlack DiamondBlackRockBloom Burton & Co.BNY MellonBoodell & CompanyBrean Capital, LLCBrinson Patrick SecuritiesBrio Capital Management LLCBurrage CapitalBurrill & CompanyBurrill SecuritiesBVF Partners LPCantor FitzgeraldCapital Royalty LPCarr SecuritiesCato BioVenturesCeltic Therapeutics Management LPCentreStone VenturesCharlestown Capital Advisors LLCChina Focus LimitedChina Private Equity GroupCitadel Investment Group

CitigroupCity National BankColumbia UniversityCowen and CompanyCrede Capital Group, LLCCritical Mass PartnersCross Current Research LLCDabar Investment AssociatesDawson James SecuritiesDeca Ventures, LLCDeerfield ManagementDiamondback CapitalDiscovery CapitalDuPont Capital MangementEagle Asset ManagementEaston CapitalEcoR1 CapitalEdgewood Management LLCEdison Investment ResearchEmerald AdvisersEmergent Rx LLCEminent Venture Capital CorporationEssex Investment Management Company, LLCEssex WoodlandsF.B. Asset ManagementF.Hoffmann-La Roche LtdFavus Institutional Research LLCFederated Kaufmann Fund FIC Capital, Inc.Fidelity InvestmentsFireRock CapitalFirst Island CapitalFountain Healthcare Partners Gagnon SecuritiesGE CapitalGem PartnersGeorge Weiss AssociatesGlobal Corporate Finance Ste.Global Energy Capital LLCGolden Seeds Angel InvestorsGoldman SachsGreat Point PartnersGreen ArrowGreenwich LifeSciencesGriffin SecuritiesGriffin Securities, Inc.GRT CapitalH.I.G. BioVenturesHBM Partners AGHermes Fund ManagersHighmount CapitalHMCHorizon Technology FinnaceHutchin Hill CapitalIliad Ventures LLCIngalls & SnyderInnotrove LLCIronridge Global Partners

ISI Group LLCIssaquena TrustJ.P. MorganJAIVCJarislowsky Fraser LtdJefferies & CompanyJHS CapitalJina Ventures Inc.JMP SecuritiesJP MorganKaminski PartnersKatz AssociatesKearny Venture PartnersKingdon CapitalKingsbridgeKnoll Capital ManagementKnott Partners, LPLadenburg ThalmannLaidlaw & CompanyLandmark Angels, Inc.Lazard Asset ManagementLedgemont Capital GroupLeviathan Biopharma GroupLifeScience Equity Partners, LLCLight Door Capital LLCLincoln Park Capital Little Gem Life Sciences FundLoeb PartnersLogical VenturesLongwood CapitalLSWorksMagna GroupMansa CapitalMaryland Biotechnology CenterMaryland Department of Business and Economic DevelopmentMaxim GroupMaximus CapitalMaz Capital AdvisorsMedical StrategyMedimmune Ventures, Inc.MedPro InvestorsMehta Partners LLCMerck & Co., IncMercury FundMillennium Management LLCMillennium Partners Green ArrowMLV & CoMorgan StanleyMorgens Waterfall VintiadisMP Healthcare Venture ManagementMSMB Capital ManagementMubadala Development CompanyMuse CapitalMVP Capital PartnerNeedham and Company

New Leaf Venture PartnersNextech Invest Ltd. NJ Investment DivisionNoble Financial Capital MarketsNordcon CapitalNowak Ventures, LLCNumoda Capital InnovationsOppenheimer & Co.Opus Point PartnersOracle PartnersOrbiMed AdvisorsOxford FinancePacific Rim VenturesPadus HealthcarePaisley and Habermas, IncPalkon Capital ManagementPappas VenturesParagon CapitalPassport CapitalPemigewasset PartnersPerceptive AdvisorsPharmakon AdvisorsPinnacle AssociatesPiper Jaffray & CoPK Healthcare PartnersPointState Capital POSCO BioVentures FundProfit InvestmentsPW PartnersQuestrion ResearchQuogue Capital LLCQVT FinancialRA Capital Management, LLCRBC Capital MarketsRevach FundRobert W. BairdRoberts MitaniRoosevelt InvestmentsROTH Capital PartnersRoundbox PartnersRoy Healthcare ResearchRoyalty PharmaRRCMRTW InvestmentsS&P Capital IQSabby CapitalSAC CapitalSamtheo Biopharma LLCSchroder Investment ManagementSector Asset ManagementSendMed CapitalSerrado CapitalSherbrook Capital Management, LLCSigma Capital ManagementSimRxSio CapitalSkyline VenturesSlack Capital Advisors

Small Business Technology Investment FundSofinnova VenturesSophrosyne CapitalSpecial Situations FundSpencer Edwards Investment Inc.Spencer TraskSR OneStanphyl CapitalStifel NicolausStone Capital MarketsStrategy Signal, LLCSummer Street Research PartnerSunTrust Robinson HumphreySurveyor CapitalSuvretta CapitalSymmetry CapitalSymphony Capital LLCSyzygy TherapeuticsTech Coast AngelsTechnological & Investment HorizonsTelemark AssociatesTerrapin Opportunity FundThe Astrologers Fund, IncThe Channel Group, LLCThe Invus GroupThe Jordan Family OfficeThe Keiser FoundationThe Livingston GroupThe R. H. Barsom Company IncThird PointThomas, McNerney & PartnersThree Arch PartnersTrellus Management TriCygnet LLCTryphon CapitalUBSUS Steel Pension fundValence Life SciencesVan Leeuwenhoeck InstituteVenBio LLCVenrockVentures West CapitalVeziris VenturesViking Global InvestorsViscogliosi Brothers, LLCVisium Asset ManagementWBB Securities LLCWK Mahon & Co.World Tech Ventures, LLCWP StewartYorkville Advisors, LLCYoung Capital Partners

*As of 01/31/2013

Participating Investors*

Participating Investors

0

300

600

900

1200

1500

2009 2010 2011 2012

Tota

l Sch

edul

ed M

eetin

gs

One-on-One Partnering Statistics

-12-

BIO One-on-One Partnering is proprietary software developed by BIO that allows selected registrants to utilize an online database tool to:

• Pre-schedule 30-minute private 1x1 meetings • Source potential collaborations and funding opportunities with an international audience • Communicate directly with prospective investors and senior management in biotech and pharma • Search company and investor profiles

One-on-One Meetings

Over 1,300 scheduled meetings in 2012

60% growth in scheduled meetings since 2009

Company & Company 9%

Investor & Investor 3%

Company & Investor 88%

Rare/Genetic Diseases: 3%

Oncology 27%

CNS 16%

Other 10%

Infectious Diseases: 7%

Autoimmune/Inflammation

5%

Metabolic 5%

Cell Therapy/Regenerative Medicine: 5%

Platform/ Discovery: 4%

Cardiovascular 4%

Gastrointestinal Disorders: 4%

Ophthalmology 4%

Vaccines: 4%Diagnostics

3%

Therapeutic Focus

Market Cap

500M-1B 7%

250-500M 11%

100-250M 19%50-100M

29%

<50M 27%

>$1B: 6%

-13-

300+ companies

Nearly 600 investors

-14-

Agenda*

Monday,February 11, 2013

Conrad Duke of Windsor Park South Basildon East Foyer Jade/Astor

4th Floor 3rd Floor7:00 – 7:55am Networking Breakfast: Grand Ballroom8:00 – 8:45am Fireside Chat with Robert Hugin, Chairman and CEO, Celgene Corporation (Astor)

9:00 – 9:25am Innovus Pharma

Oxygen Biotherapeutics

Proteon Therapeutics Galena BioPharma GTx Show Me

the Money: Reimbursement in an ACA World

(Jade)

Tobira Therapeutics

9:30 – 9:55am Verastem Transition Therapeutics

Regado Biosciences Oncolytics Biotech ChemoCentryx

ALS TDI (PAG)

10:00 – 10:25am Advanced Cell Technology DiaMedica

CoLucid Pharmaceuticals ImmunoCellular

TherapeuticsRigel

PharmaceuticalsActinium Pharmaceuticals

10:30 – 10:55am ReNeuron GENFITOnconova Therapeutics Furiex

PharmaceuticalsNPS

PharmaceuticalsOncolog y: Panning for

Gold—Prospecting the Pancreatic Pipeline (Jade)

uniQure

11:00 – 11:25am Palatin Technologies CEL-SCI Corporation

Fate Therapeutics Repros Therapeutics

Lexicon PharmaceuticalsZafgen

11:30 – 11:55am NovaBay Pharmaceuticals

Provectus Pharmaceuticals

LL Society (PAG)TONIX

Pharmaceuticals AgenusFive Prime Therapeutics

12:00 – 12:55pm Opening Plenary Session: Word on the Street – Buy-Side View for 2013 (Jade) – Box Lunch

1:00 – 1:25pm Anteo Diagnostics Atossa Genetics

Catabasis Pharmaceuticals

Targacept Synergy Pharmaceuticals

Fireside Chat with John

Lechleiter, PhD, Chairman,

President and CEO, Eli Lilly

(Astor, 1:00-1:45pm)Promedior

1:30 – 1:55pm ProMetic Life Sciences CytRx Corporation

KineMedBiotie Therapies Cytokinetics

TVAX Biomedical

2:00 – 2:25pm NeoStem Novelos TherapeuticsGood Start Genetics Cleveland

BioLabsZealand

Pharma A/SHow the Other

Half Lives: What’s Happening

in Venture and Why it Matters

(Jade)

Radius Health

2:30 – 2:55pm Opexa Therapeutics VirtualScopics

Mirna TherapeuticsCyclacel

Pharmaceuticals

Keryx Biopharma-

ceuticalsMelanoma Research Alliance (PAG)

3:00 – 3:25pm Idera Pharmaceuticals Biodel Oculus Innovative

Sciences MDxHealth Novavax

3:30 – 3:55pm Q Therapeutics Eternity Healthcare Antisense Therapeutics TG Therapeutics Navidea Small Companies

Thinking Big: China Tactical

Strategies(Jade)

4:00 – 4:25pmCatalyst

Pharmaceutical Partners

RXi Pharmaceuticals Venaxis Anthera Pharmaceuticals Stallergenes

4:30 – 4:55pm Cytomedix Ohr Pharmaceutical Tranzyme Horizon Pharma

Intercept Pharmaceuticals

5:00 – 6:30pm BIO CEO Reception (Empire Room)

* As of 1/31. Program schedule subject to change. Please go to www.bio.org/bioceo or visit us onsite for updates.

-15-

Tuesday,February 12, 2013

Conrad Duke of Windsor Park South Basildon East Foyer Jade/Astor4th Floor 3rd Floor

7:00 – 7:40am Networking Breakfast (Grand Ballroom)

7:45 – 8:25am Fireside Chat with N. Anthony Coles, MD, Chairman & CEO, Onyx Pharmaceuticals (Astor)

8:30 – 8:55am TiGenix N.V. StemCellsPolynoma

OvaScience ExelixisTrevena

9:00 – 9:25am Athersys ZalicusSutro Biopharma

Resverlogix Corp. ImmunoGen Orphan Drugs:

Making Rare Diseases Rarer

(Jade)

Syndax Pharmaceuticals

9:30 – 9:55am Inovio Pharmaceuticals Neuralstem

GlobeImmune

Cempra AffymaxAratana Therapeutics

10:00 – 10:25am Apricus Biosciences

ADVENTRX Pharmaceuticals

Immune Design Corp. ZIOPHARM

OncologyACADIA

PharmaceuticalsFORMA Therapeutics

10:30 – 10:55amTekmira

Pharmaceuticals Corp.

Tengion

Mersana Therapeutics Nymox

Pharmaceutical Corporation

AegerionKinex

Pharmaceuticals

11:00 – 11:25am Synthetic Biologics DURECT Corporation

MJFF (PAG)

Adocia Raptor Pharmaceutical

Fireside Chat with John Milligan, PhD,

President and COO, Gilead Sciences (Astor)

Hydra Biosciences

11:30 – 11:55am NanoViricides Prima Biomed Ltd.

Prosensa Therapeutics Astex

PharmaceuticalsProtalix

BioTherapeuticsKaloBios Pharmaceuticals

12:00 – 12:55pm(Box Lunch)

Business Development: Putting a Ring on It—When Drug Development Deals

Turn into Acquisitions (Astor)

Oncology: The CLL Chronicles—

The Next Chapter in Clinical Developments (Jade)

1:00 – 1:25pm OncoGenex Pharmaceuticals Regulus Therapeutics pSiVida Corp. Sucampo

Pharmaceuticals Alkermes plc

1:30 – 1:55pm Oragenics Immunovaccine iCo Therapeutics

BioDelivery Sciences

International

Arena Pharmaceuticals

The Road Less Traveled:

Alternative Avenues to Public Markets

(Jade)2:00 – 2:25pm BioLineRx Ltd. Aradigm Corp. DARA BioSciences

SciClone Pharmaceuticals Orexigen

2:30 – 2:55pm Transcept Pharmaceuticals GeoVax Labs EpiCept

CorporationAddex

Therapeutics Alnylam

Pharmaceuticals

3:00 – 3:25pmNewron

Pharmaceuticals S.p.A

Soligenix OncoSec Medical

Aastrom Biosciences

Idenix Pharmaceuticals

3:30 – 3:55pm Pozen Retrophin OXiGENE NicOx S.A. Islet Sciences

Fireside Chat with JJ Bienaimé

CEO, BioMarin (Astor)

4:00 – 4:55pm Closing Plenary: Tales From the Wild West (Wing): Reflections from White House Chiefs of Staff (Jade)

5:00 – 6:00pm Closing Happy Hour (Silver Corridor)

Conference Size 1,150+

One-on-One PartneringTM Meetings 1,300+

Investors Attending 600

Company Presentations 140

Audience Profile

-16-

Who Should Attend?

Associate 10% Other

7%

Executive 36%Manager

10%

V.P. 11%

Analyst 11%

Director 15%

Attendees by Title

Over 1,100 attendees from 16 different countries

Over 35% of attendees are executives

-17-

BIO offers a number of ways for conference attendees to save money on their registration fees.

Discounted packages for presenting companies bringing three or more attendees.

Special rates for academics and service providers.

Complimentary registration is available to qualified institutional (buy and sell-side), private equity, and venture investors.

Go to bio.org/bioceo/register and register now.

Join the conversation:Learn more about Biotechnology at bio.orgEngage with the Biotech Community at BIOtech-NOW.orgFollow us on Twitter @bio1x1 or #BIOCEO13Become a fan on Facebook (facebook.com/IAmBiotech)

Academic Service Providers InvestorsPublic Company Private Company-New! Public Company Private Company-New! Additional Attendee Registration Fee Registration Fee Registration Fee

Early Rate$5,785 members$8,295 non-members

$4,795 members$7,095 non-members

$1,495 members$2,195 non-members

$1,495 members $2,195 non-members

$1,095 members $1,695 non-members

$895 members $895 non-members

$3,195 members $4,195 non-members Complimentary

Late Rate$6,396 members$9,295 non-members

$5,395 members$8,095 non-members

$1,895 members$2,895 non-members

$1,895 members $2,895 non-members

$1,395 members $2,895 non-members

$895 members $895 non-members

$4,195 members $5,195 non-members Complimentary

Presentation

Additional rate:$2,895 members $3,795 non-members

Additional rate: $1,895 members $2,595 non-members

Presenter Registration

Early additional attendee:$1,095 members$1,695 non-members

Early additional attendee:$1,095 members$1,695 non-members

Late additional attendee:$1,395 members$2,895 non-members

Late additional attendee:$1,395 members$2,895 non-members

1x1 PartneringOpening ReceptionNetworking BreakfastsAttend Company PresentationsProgramming Panels

Early Member Rate Total:

3 people with presentation: $5,785

3 people with presentation: $4,795

1 person with presentation: $4,390

1 person with presentation: $3,390

2 people with presentation:Public- $5,785 Private- $3,485

Early Non- 2 people with presentation:

Group Package: 3+ People Individual Packages: 1-2 people

2 additional registrations

Member Rate Total:

3 people with presentation: $8,295

3 people with presentation: $7,095

1 person with presentation: $5,990

1 person with presentation: $4,790

Public- $7,685 Private- $6,485

Book now and save 10%!

Reserve your space today!

3

3

3

SponsorsSupporting Bank Sponsors

BIO Double Helix Sponsors BIO Helix Sponsors

Conference Supporters

Media Partners

Local Co-Host

Contact us today for a tailored sponsorship package to meet your business objectives. Contact Matt Lowe at mlowe@bio.org or call 202.312.9277. For more information on BIO sponsorships, please visit www.bio.org/sponsor

Member FINRA/SIPC

bio.org/eventsA Vital Business Catalyst.

Vienna, AustriaNovember 4-6, 2013

January 2014New York CityFebruary 10-11, 2014

Barcelona, SpainMarch 11-13, 2013

The BIO Convention in ChinaTM

Beijing, ChinaFall 2013

BIO Investor ForumTM

San FranciscoOctober 8-9, 2013